RecruitingNCT03478553
The Genetics of Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis, a Disease Initiated by Mucociliary Dysfunction
Sponsor
University of Colorado, Denver
Enrollment
1,000 participants
Start Date
Jan 18, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Age at least 18 years old
- Family member diagnosed with IPF
Exclusion Criteria1
- \- No family member with IPF
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERBlood draw
Blood draw
OTHERQuestionnaire
Pulmonary Fibrosis Questionnaire
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03478553
Related Trials
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT0695121752 locations
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT069688459 locations
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
NCT070828421 location
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
NCT073445588 locations
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
NCT071943823 locations